# A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures

> **NCT01185028** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 8 (actual)

## Conditions studied

- Hepatitis C Infection
- HIV Infection

## Interventions

- **DRUG:** Nitazoxanide With Pegylated Interferon And Ribavirin

## Key facts

- **NCT ID:** NCT01185028
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2021-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01185028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01185028, "A Safety and Tolerability Study of Nitazoxanide in HIV-HCV Treatment Failures". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01185028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*